Premarket Movers Today — Live Gainers Before the Bell
Premarket movers today (Sep 22): DCOY +38.7%, VKTX +38.2%, BFLY +21.9% — live gainers and losers before the bell (4:00-9:30 AM ET), ranked by real-time RVOL and refreshed continuously. Gaps often trace to overnight earnings, FDA news, or macro headlines already priced in before the open.
What are today's premarket movers?
Today's biggest premarket movers are DCOY (+38.70%), VKTX (+38.16%), BFLY (+21.87%), ranked by premarket RVOL and sourced from the live 15-minute-delayed scanner feed. Gaps often trace to overnight earnings, FDA news, or macro headlines already priced in before the open; the 4:00–9:30 AM ET session is thinnest from 4:00 to 7:00 AM and heaviest into the bell. See today's live leaderboard with real-time RVOL, the full RVOL methodology, and 15-minute-delayed data at tapeboard.com/movers/premarket.
Leader right now: DCOY +38.70% at $3.53. Sourced from the live 15-min-delayed scanner snapshot above.
// As of September 22, 2026 · delayed 15 min
What's moving the tape on DCOY, grounded in Tapeboard's data. Not investment advice.
As of
- Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline — Benzinga - Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference — Yahoo
- The company is exploring non-dilutive federal grants and public health collaborations to support its biodefense pipeline. - The recent news suggests that the company is actively seeking partnerships and funding to advance its research.
- The company has a history of significant losses, with a net income of -$12518480 in 2025 and -$5575777 in 2024. - The company's operating expenses have been increasing, with $12613952 in 2025 and $5734316 in 2024.
- The company has a high short interest ratio, with a squeeze score of 9.9 and 0.49 days to cover. - The company's revenue and gross margin are not available in the data.
- The company's future revenue and profitability are uncertain due to the lack of available data. - The company's ability to secure non-dilutive federal grants and public health collaborations is not guaranteed. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on VKTX, grounded in Tapeboard's data. Not investment advice.
As of
- "Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing" (Benzinga) - "Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735… 22% Placebo-Adjusted Weight Loss Reported At Week 33" (Benzinga)
- Strong analyst consensus: 9 strong buys, 14 buys across multiple future periods. - High RVOL (28.96x) and day volume 33.2M indicate intense buying interest.
- Recent SeekingAlpha headline: "The Market Might Shrug Off The Maintenance Data" suggests skepticism. - Negative earnings: net income -$0.36B FY2025, EPS -3.19, PE -8.33.
- Squeeze score 34.8/100 (moderate) and days to cover 12.6 signal potential short‑squeeze volatility. - No revenue (SEC shows $0) and continued cash‑flow burn (-$278.7M operating FY2025).
- Exact timing and magnitude of future VK2735 regulatory milestones are not disclosed. - Future dilution risk from potential financing needs given ongoing losses. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BFLY, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up 17.38% on heavy volume (RVOL 4.37x) vs prior close $8.14
- Revenue grew +19% YoY to $0.10B with improving gross margin 46.9% - Analyst estimates consistently show strong buy/buy consensus across multiple periods
- Net income remains negative ($-0.08B) and EPS is negative (-0.31) - Operating cash flow negative (-$12.7M) and free cash flow negative (-$16.0M)
- High price-to-sales ratio (22.5) suggests rich valuation relative to sales - Short interest data limited; easyToBorrow flag is false, indicating potential borrowing constraints
- No forward guidance or upcoming catalysts disclosed in the provided data - Lack of recent news leaves uncertainty about any near‑term operational developments --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on OMER, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up $1.65 (+8.9%) on volume 1.05M, RVOL 2.47x indicating heightened activity
- Shares trading above 52‑week high ($19.65) showing strong upward momentum - Short interest modest (days to cover 5.5, squeeze score 28.9) limiting downside pressure
- FY 2025 net loss of $3.35M and negative EPS (-$0.05) reflect ongoing unprofitability - Negative book value per share (-$0.71) and PB ratio -28.3 signal balance‑sheet weakness
- Operating cash flow negative for FY 2025 (-$116M) and FY 2024 (-$149M) - Easy‑to‑borrow flag false, suggesting potential borrowing constraints for shorts
- No forward guidance or pipeline updates provided in the data - Unclear timing of any potential catalysts driving the current price move --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on GRAB, grounded in Tapeboard's data. Not investment advice.
As of
- "Why Is Grab Stock Trading Higher Today?" highlights CEO and COO insider purchases of ~10.65 M shares worth >$30.7 M. - "Grab to Buy 60% of Atome for $1.49B, Raises 2028 Growth Targets" announces a controlling stake in Atome Financial and lifted long‑term guidance.
- Analyst estimates show strong consensus: 10 Strong Buy, 17 Buy, 2 Hold across multiple periods. - Recent earnings surprises were large (+157.5% Q2 2026, +88.7% Q1 2026) and the company completed a share‑repurchase plan.
- The stock sits near the bottom of its 52‑week range (12% of the range) with a high P/S of 3.49, suggesting stretched valuation. - Squeeze score is modest (33.8/100) and days to cover short interest are 6.8, limiting short‑squeeze potential.
- Short interest is 261.65M shares (≈8.7% of float) and the stock is not easy to borrow (easyToBorrow: false). - RVOL is elevated at 3.36×, indicating unusually high trading activity that could reverse quickly.
- How the Atome acquisition will integrate and impact profitability remains unclear. - Broader macro‑economic conditions in Southeast Asia and consumer‑spending trends are not detailed in the data. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on OPEN, grounded in Tapeboard's data. Not investment advice.
As of
- Opendoor Gains 5% but Is Still Down 24% in a Month. Will the Bulls or Bears Win? — Yahoo - Rate Hike Jitters Rattle iBuyer Stocks: Opendoor Falls 4%, Zillow Slides 2% but Offerpad Holds Steady — Yahoo
- Recent revenue growth (4.37B in 2025) could support a potential turnaround - Analysts have maintained an Overweight rating on Opendoor Technologies
- Revenue YoY: -15.2% vs prior year - Net income: -$1.30B in 2025, with a net income margin of -30.0%
- Days to cover: 5.1, indicating a relatively high short interest - Squeeze score: 21/100, indicating a potential squeeze in the short position
- No clear catalyst for the recent price increase - Uncertainty surrounding the company's ability to turn around its revenue and net income --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on CRM, grounded in Tapeboard's data. Not investment advice.
As of
- "Why Is Salesforce Stock Falling Thursday?" — Benzinga notes CRM dips 3% despite raising FY27 revenue outlook. - "Agentforce Triggers Renewal Surge, Sparking Salesforce AI Boom: Analyst" — Benzinga highlights AI-driven renewal momentum.
- Revenue grew +9.6% YoY to $41.5B with gross margin 77.7% and net income $7.46B (SEC 2026). - Analyst consensus shows strongBuy/Buy dominance (14 strongBuy, 30 Buy for Sep‑2026 estimates).
- Stock down -0.36% today, trading below 52‑week midpoint and near recent 3% dip on negative news. - Valuation metrics: P/E 21.5, P/B 5.06, P/S 4.42 suggest premium pricing relative to peers.
- Short interest 29.2M shares (≈3.7% of float) with days to cover 1.9 and squeeze score 28.6/100. - RVOL 0.68x indicates below‑average trading activity, limiting liquidity.
- Timing and scale of monetizing Agentforce and Koa AI models remain unclear. - Impact of potential Anthropic stake sale on debt reduction and share‑repurchase plans is unspecified. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on FISV, grounded in Tapeboard's data. Not investment advice.
As of
- Fiserv Expands Clover Footprint in Canadian Sports and Entertainment — Yahoo - FISV Stock Plunges To 52-Week Low: Why Is Retail Still Bullish? — Yahoo - Fiserv Targets Turnaround With Project Elevate, AI and Clover Growth — Yahoo
- P/E ratio of 8.9 suggests the stock is cheap relative to earnings. - Analyst estimates show a majority of buy/hold ratings across multiple future periods.
- Price is only 1% above the 52‑week low of $45.88, indicating strong downward pressure. - Recent earnings surprise was negative (‑5.5% in Q2 2026) and Q3 2025 missed by ‑24.3%.
- RVOL of 0.77x shows trading volume below average, limiting liquidity. - Total liabilities exceed $54 billion, reflecting a leveraged balance sheet despite modest net debt.
- The effectiveness of Project Elevate and AI initiatives on future revenue is unclear. - How broader economic trends will affect merchant‑solution demand remains uncertain. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on AMC, grounded in Tapeboard's data. Not investment advice.
As of
- AMC Entertainment Holdings (AMC) Launches $3.97 Billion Debt Refinancing Initiative — Yahoo - AMC Spikes 7% as Refinancing Pushes Maturities From 2029 to 2031; Cinemark and IMAX Edge Higher — Yahoo
- Recent debt refinancing initiative could provide AMC with much-needed breathing room and delay a potential reckoning. - The company's revenue has been increasing, with a 4.6% year-over-year growth in revenue.
- AMC's net income has been negative, with a net loss of $632.4 million in 2025. - The company's total debt is $4.038 billion, which is a significant burden on its financial health.
- AMC's short interest is high, with 1.69 days to cover and a squeeze score of 19.8/100. - The company's float is 835,344,050 shares, which is a large number of shares that could be affected by short selling.
- The long-term impact of AMC's debt refinancing initiative is unclear, and it remains to be seen whether it will be enough to turn the company's financial health around. - The company's ability to generate revenue and turn a profit in the future is uncertain. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on INOD, grounded in Tapeboard's data. Not investment advice.
As of
- "Cerebras Systems vs. Innodata: Which AI-Driven Tech Stock Is a Better Buy in 2026?" — Yahoo - "Innodata's Customer Diversification Effort: Is It Finally Paying Off?" — Yahoo
- Revenue up 47.6% YoY with Q2 2026 EPS surprise of +89.6% and Q1 surprise of +446.9% - Analyst consensus shows 9 strong buys/buys vs 1 hold across multiple 2026 periods
- Stock still down ~47% over the last 3 months per recent headline - P/E ratio ~53 and P/S ~7.6 indicate premium valuation relative to peers
- Short interest days to cover 3.1 with easyToBorrow flag false, suggesting borrowing constraints - Squeeze score low at 19.7/100, limiting short‑squeeze potential
- No clear forward guidance on FY 2027 revenue or margin expansion - Uncertain impact of new board appointment (Admiral Rogers) on federal contract pipeline --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on MSFT, grounded in Tapeboard's data. Not investment advice.
As of
- Recent news: "Microsoft’s Azure Has Another Growth Lever Waiting in the Wings, Analyst Says" - benzinga - Recent news: "This Analyst Raises Price Targets For Microsoft And This AI Infrastructure Stock" - benzinga
- Revenue growth: +17.8% YoY vs prior year - Strong financials: gross margin 67.9%, net income $133.75B
- Price decline: -3.31 (-0.66%) in one day - High short interest: 2.5 days to cover
- High short interest: 2.5 days to cover - Low squeeze score: 21/100
- No recent news available in the data --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on VOYG, grounded in Tapeboard's data. Not investment advice.
As of
- Voyager Stock Tanks After Hours — Here's Why (benzinga) – notes a $350 M convertible‑notes offering driving the after‑hours drop. - RKLB, ASTS, VOYG, LUNR Steal SpaceX’s Thunder — Here’s What Lit Up Space Stocks This Week (Yahoo) – highlights broader space‑stock rally that VOYG is part of.
- Analyst consensus shows strong buying bias (8 strong‑buy, 6 buy across recent periods). - Revenue grew +15.4% YoY and Q2 2026 EPS beat estimates by +33.8%.
- Net income remains negative (‑$0.10B FY2025) with operating cash flow of ‑$60.9M. - Valuation multiples are elevated (P/S 12.8, P/B 6.8) despite no profit.
- Short interest is 9.18M shares (≈16.7% of float) with days to cover 5.5, indicating potential squeeze pressure. - RVOL at 0.71x shows below‑average trading interest, limiting liquidity.
- Impact of the newly announced $350 M convertible‑notes offering on dilution and debt load. - Timeline and revenue contribution from the Starlab Space JV and microgravity research initiatives. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BNGO, grounded in Tapeboard's data. Not investment advice.
As of
- Bionano Genomics Stock Surges Tuesday: What's Going On? — Benzinga - Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping — Yahoo
- Analyst estimates show strong buy/buy consensus across multiple periods (2‑5‑1‑0‑0). - Recent earnings surprises were positive, with Q4 2025 beating estimates by ~98%.
- Revenue fell 7.4% YoY to $0.03B and net income remained negative ($‑0.03B). - RVOL is low at 0.19x and the stock is down 0.55% on modest volume (883k).
- Operating cash flow was negative $16.3M FY2025; financing cash flow relied on $24M inflow. - Short interest days to cover is 8.0, indicating moderate bearish pressure.
- Outcome of the proposed MolDX Local Coverage Determination for genome‑wide detection. - Timeline for cash‑flow turnaround given continued operating losses. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
See this live in the Tapeboard scanner
This table is baked at build time and never moves. The scanner runs the same scan continuously, streaming and filterable, with a chart and research pane one click away on every row. Free, no account needed.
Open the live premarket gap-up scannerWhat are the biggest premarket movers today?
- // Tracks stocks moving premarket from 4:00 AM to 9:30 AM ET, updated continuously
- // Premarket volume floor at 50K shares to filter single-print noise
- // Sorted by premarket RVOL so the biggest anomalies surface first
- // News and earnings flags layer on top where available
- // Cross-checks against the gap-and-go scanner for confluence
- // Streaming real-time. Rows update as prints land, not on a 10-second refresh delay.
- // Click any ticker for the full research pane: chart, Level 2, time & sales, filings, insider activity, news recency.
- // 15-minute delay on the public surface; signed-in users see the live tape without delay.
- // Free to view. No card. No paywall on this page.
Frequently asked questions about today's market movers
// Other movers categories you might want next to this one:
Watch the movers live on Tapeboard.
// 28 sec to first scanner · no card · cancel anytime
Start free View pricing See it live in the scanner